Terbinafine transdermal - Hisamitsu

Drug Profile

Terbinafine transdermal - Hisamitsu

Alternative Names: HTU-520; Terbinafine-hydrochloride-patch

Latest Information Update: 11 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Onychomycosis

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 11 Apr 2013 Terbinafine transdermal is still in phase III trials for Onchomycosis in Japan and phase II trials in US
  • 31 Jan 2013 Hisamitsu completes a phase II trial in Onchomycosis in US (NCT01400594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top